{"id":653,"date":"2015-02-11T10:10:32","date_gmt":"2015-02-11T10:10:32","guid":{"rendered":"http:\/\/europeanvenousforum.org\/?page_id=653"},"modified":"2023-03-31T14:29:54","modified_gmt":"2023-03-31T14:29:54","slug":"senior-corporate-members-2","status":"publish","type":"page","link":"https:\/\/europeanvenousforum.org\/index.php\/ev-foundation\/senior-corporate-members-2\/","title":{"rendered":"Corporate Members"},"content":{"rendered":"

Corporate Members<\/span><\/h1>\n

Opportunities are available for companies to join us as Corporate Members. The cost per annum starts at \u20ac5,000. If you are interested, please contact Anne Taft at the EVF office<\/span> (<\/span>admin@europeanvenousforum.org<\/a>) for further information.<\/span><\/em><\/p>\n

\n

 <\/p>\n

\"\"<\/a><\/p>\n

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections and is also active in the treatment of vascular diseases. <\/span>It operates in about 100 countries thanks to a strong network of international partners and invests its profits in R&D to develop microbial derived immunotherapeutic products to treat acute and chronic immunological disorders resulting from inflammation and infections.<\/span><\/p>\n

On 30 September 2020, Etienne Jornod, former Executive Chairman of Vifor Pharma and Galenica, acquired the company together with entrepreneurs and strategic partner, Abdi Ibrahim, with the ambition to continue its global expansion and to invest CHF 250 million in R&D and manufacturing capacity expansion. <\/span>The company strives to improve the quality of life of patients around the world by providing access to better treatment of immunological imbalances.<\/span><\/p>\n

For more information, visit<\/span> www.ompharma.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Corporate Members Opportunities are available for companies to join us as Corporate Members. The cost per annum starts at \u20ac5,000. If you are interested, please contact Anne Taft at the EVF office (admin@europeanvenousforum.org) for further information.   OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in \u2026 Continue reading → <\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":89,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/template-onecolumn.php","meta":{"_exactmetrics_skip_tracking":false,"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-653","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/comments?post=653"}],"version-history":[{"count":12,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/653\/revisions"}],"predecessor-version":[{"id":9427,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/653\/revisions\/9427"}],"up":[{"embeddable":true,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/89"}],"wp:attachment":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/media?parent=653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}